

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

February 18, 2020

Via E-mail
Emily Hill
Chief Financial Officer
PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield, NJ 07080

**Re:** PTC Therapeutics, Inc.

From 10-Q for the quarterly period ended September 30, 2019

Exhibit 10.5 - Lease Agreement dated as of August 3, 2019, by and between Bristol-

Myers Squibb Company and PTC Therapeutics, Inc.

Filed October 30, 2019 File No. 001-35969

Form 8-K

 ${\bf Exhibit\ No.\ 2.1\ -\ Asset\ Purchase\ Agreement\ by\ and\ between\ PTC\ The rapeutics,\ Inc.}$ 

and BioElectron, dated October 1, 2019

Filed October 30, 2019 File No. 001-35969

Dear Ms. Hill:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance